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Angiotensin converting enzyme 2 (ACE2) is localized to the
glomerular epithelial cells. Since ACE2 promotes the
degradation of angiotensin II, a decrease in ACE2 activity
could lead to the development of glomerular injury. We gave
a specific ACE2 inhibitor, MLN-4760, for 4 weeks to mice
rendered diabetic with streptozotocin. The urinary
albumin/creatinine ratio was increased along with expansion
of the glomerular matrix in diabetic mice treated with the
inhibitor compared to the vehicle-treated mice. Glomerular
staining of ACE was increased in the diabetic group and was
further significantly increased in the diabetic group treated
with MLN-4760. In renal vessels, ACE expression was also
increased in the diabetic mice and, again, further increased in
those diabetic mice treated with the ACE2 inhibitor. Our
study shows that chronic pharmacologic ACE2 inhibition
worsens glomerular injury in streptozotocin-induced diabetic
mice in association with increased ACE expression.
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Angiotensin converting enzyme (ACE), a dipeptidyl carboxy-
peptidase, is a key enzyme of the renin angiotensin system
(RAS) that converts angiotensin (Ang) I to II.1 (ACE)-2 is a
homologue of ACE, which shares 42% sequence identity to
the N- and C-terminal domains of somatic ACE.1–3 ACE2
cleaves Ang II into Ang 1-7 and degrades Ang I to Ang
1-9.2,4,5 We first advanced the notion that ACE2 could be
renoprotective in diabetic mice, particularly in combination
with reduced ACE activity.6 In support of this concept, we
have shown that the pharmacological inhibition of ACE2
worsens albuminuria in the db/db model of diabetes.7 The
importance of this enzyme is also apparent from recent
studies with the ACE2 knockout showing that male, but not
female, mice developed renal pathological lesions.8 Other
studies in ACE2 knockout have suggested an important role
of this enzyme in protecting against lung injury9 and an
exaggerated blood pressure increase after Ang II infusion.10
Because the RAS plays a key role in renal injury,11–13
there is increasing interest in examining ACE2 expression in
the kidney, particularly in diabetic nephropathy.6,7,14 We have
shown recently that in the kidney, ACE and ACE2 are
localized within distinct glomerular structures.7 ACE2 was
expressed mainly in visceral epithelial cells (podocytes), and
in parietal epithelial cells of the Bowman’s capsule. Moreover,
we found that ACE2 protein expression in glomeruli from
db/db mice was decreased, whereas ACE protein expression,
by contrast, was increased.7 It should be noted that in the
db/db mice, the pattern of tubular expression of ACE and
ACE2 (i.e., low ACE and high ACE2) is just the opposite
than that seen in glomeruli.6,15 In the present study,
we investigated the effect of chronic pharmacological ACE2
inhibition in the streptozotocin (STZ) model of diabetes in
terms of (1) histological damage, (2) albumin excretion rates,
and (3) ACE expression.
RESULTS
General findings
Eight weeks after STZ administration, blood glucose was
increased as compared to control mice of similar age
(19 weeks of age) (Table 1). In STZ-treated mice given
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MLN-4760, glucose levels were not significantly different
from STZ-treated mice given vehicle (Table 1). An increase in
both, right and left kidney weight was observed in STZ-
treated mice as compared to non-diabetic controls. STZ-
treated mice given MLN-4760 had a modest but significant
decrease in body weight, but a significant increase in kidney
weight as compared to STZ mice given vehicle (Table 1).
Therefore, the ratio of kidney/body weight was increased in
STZ-treated mice and further increased in STZ-treated mice
given MLN-4760 (Table 1).
There were significant differences in urinary albumin
excretion between the three groups studied (Figure 1). In STZ
mice treated with vehicle, urinary albumin excretion was
approximately 10-fold higher than in vehicle treated non-
diabetic controls (237788 vs 2275 mg/mg, respectively,
Po0.05) (Table 1). After 4 weeks of MLN-4760 administra-
tion to STZ-treated mice, urinary albumin excretion
was significantly higher than in STZ mice treated with
vehicle (11077251 vs 237788 mg/mg, respectively, Po0.05)
(Figure 1).
ACE2 activity and mRNA expression
ACE2 activity was measured in kidney cortex from STZ mice
treated with MLN-4760 and the vehicle-treated STZ counter-
parts. ACE2 activity in kidney cortex from STZ mice given
MLN-4760 for 4 weeks was decreased as compared to vehicle-
treated animals also given STZ (1.1370.15 RFU (relative
fluorescence units)/mg protein/h vs 12.371.6, respectively,
Po0.001). This represents a 90% inhibition by MLN-4760 as
compared to STZ mice given vehicle. ACE2 mRNA was
decreased in kidney cortex from STZ mice given MLN-4760,
as compared to STZ mice given vehicle also for 4 weeks
(0.6370.08 vs 1.1070.24, respectively, Po0.05).
MLN-4760 specificity
MLN-4760 has been shown to specifically inhibit ACE2
activity of purified human recombinant ACE2 protein.15 We
wanted to test the specificity of this compound for murine
ACE2 protein.
We tested the inhibitory effect of MLN-4760 on mouse
recombinant (mr)ACE2 (20 nM; R&D Systems, Minneapolis,
MN, USA) at concentrations ranging from 100 pM to 100 mM
(Figure 2a). MLN-4760 quenched the fluorescence signal
completely at 1 mM (Figure 2a). The ACE inhibitor, captopril,
by contrast, failed to quench fluorescence when incubated
with mrACE2 at a concentration up to 100 mM (Figure 2a).
MLN-4760 specificity was also shown in isolated mouse
glomeruli and renal cortex. MLN-4760 (1 mM) did not inhibit
ACE activity either in glomerular isolates or in renal cortex
(Figure 2b and c), whereas captopril at the same concentra-
tion reduced it to 35.3%717.6 and 8.4%71.9 of control,
respectively.
Effect of MLN-4760 on plasma levels of Ang II
There was no significant difference in the plasma levels of
Ang II between control and STZ mice (36.1716.5 vs
45.4712.2 fmol/ml, respectively, P¼ 0.62). Moreover, plasma
Ang II levels in STZ mice given MLN-4760 were not
significantly different as compared to STZ mice treated with
vehicle (37.4710.4 vs 45.4712.2 fmol/ml, respectively,
P¼ 0.66).
Renal histological findings
The light microscopy findings in kidneys from control,
vehicle-treated STZ mice, and MLN-4760-treated STZ mice
are summarized in Table 2. Glomerular mesangial matrix was
increased in STZ-treated mice as compared to non-diabetic
controls (Figure 3b and a, respectively), and further increased
in STZ mice receiving MLN-4760 (Figure 3c). A semiquanti-
tative analysis revealed a significant increase in MLN-4760-
treated STZ mice as compared to STZ mice treated with
vehicle (Table 2). Using computer-linked image analysis, the
glomerular tuft area was increased in both STZ-treated
groups compared to the non-diabetic control group (Table 2).
Table 1 | Effect of MLN-4760 on STZ-treated mice
Control+vehicle STZ+vehicle STZ+MLN-4760
n 5 10 14
Blood glucose (mg/dl) 154.678.4 438.2749.1* 501.1739.3w
Body weight (g) 21.870.4 20.070.6* 18.370.4w,z
Right kidney
weight (mg)
137.875.4 180.978.0* 217.6710.6w,z
Ratio kidneys/body
weight
0.01270.0004 0.01870.001* 0.02370.001w,z
Albuminuria/creatinine
(mg/mg)
21.675.3 236.7788.0* 1107.47250.9w,z
Control+vehicle (n=5): non-diabetic control mice given vehicle; STZ+vehicle (n=10):
streptozotocin-induced diabetic mice given vehicle; STZ+MLN-4760 (n=14): STZ
mice given MLN-4760.
Data are expressed as means7s.e.
*Po0.05 control+vehicle vs STZ+vehicle.
wPp0.001 control+vehicle vs STZ+MLN-4760.
zPp0.05 STZ+vehicle vs STZ+MLN-4760. Mann–Whitney test.
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Figure 1 | Urinary albumin/creatinine ratio after 4 weeks of
MLN-4760 or vehicle administration. Each point reflects data from
one animal in each group. The mean7s.e. of the three groups is
significantly different (Po0.05).
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There was no significant difference in glomerular size
between the STZ-treated mice receiving vehicle or MLN-
4760 (Table 2). Glomerular cellularity was increased in STZ
mice treated with vehicle as compared to the non-diabetic
control group (Figure 2b and a, respectively). MLN-4760-
treated STZ mice, however, had decreased glomerular
cellularity as compared to vehicle-treated STZ mice (Table 2).
In renal arterioles from STZ mice, the tunica media layer
showed increased thickness as compared to non-diabetic
controls, and in MLN-4760-treated STZ mice, vascular
thickness increased as compared to vehicle-treated STZ mice
(Table 2).
In vehicle- and MLN-4760-treated STZ mice, light
photomicrographs of kidney sections revealed atrophy of
medulla (Figure 4). Atrophy of the medulla and its tubules
was most notable in MLN-4760-treated STZ mice. By
contrast, tubular hypertrophy was observed in the cortical
area (Figure 4), as reported previously in STZ-induced
diabetic rats.16 Tubular enlargement was seen in both STZ
groups, but tubules with enlarged nuclei were readily seen in
the MLN-4760-treated group, suggesting accentuated hyper-
trophic response in this group. That MLN-4760-treated mice
had tubular hypertrophy can also be inferred from the
increased kidney weight and kidney/body weight ratio in
MLN-4760-treated STZ mice as compared to vehicle treated-
STZ mice (Table 1).
In the tubulointerstitial area, fibronectin and collagen I
staining were increased significantly in STZ-treated mice as
compared to the non-diabetic control group (Table 2). In
MLN-4760-treated STZ mice, fibronectin and collagen I
expression were increased as compared to STZ mice treated
with vehicle, but the difference did not reach statistical
significance (Table 2). The two markers of fibrosis were
further quantified at the mRNA level. Concordant with the
immunostaining findings, fibronectin mRNA was increased
in kidney cortex from STZ mice treated with vehicle as
compared to non-diabetic controls (12.8172.58 vs
1.1370.06 respectively, P¼ 0.001). There was no significant
difference in fibronectin mRNA in renal cortex between the
STZ mice receiving vehicle and MLN-4760 treated animals
(12.8172.58 vs 15.5071.91 respectively, P¼ 0.41). Likewise,
Mouse recombinant ACE2
MLN-4760
Captopril
140
120
100
80
60
40
20
–20
0
%
 c
on
tro
l
10
0 p
M
1 n
M
10
 nm
10
0 n
M
1 u
M
1 m
M
10
 uM
10
0 u
M
Mouse glomeruli
Mouse kidney cortex
AC
E 
ac
tiv
ity
 (%
 co
ntr
ol)
140.0
120.0
100.0
80.0
60.0
40.0
20.0
0.0
AC
E 
ac
tiv
ity
 (%
 co
ntr
ol) 140.0120.0
100.0
80.0
60.0
40.0
20.0
0.0
CNTRL MLN-4760
CNTRL MLN-4760
Figure 2 | (a) The effect of MLN-4760 on murine recombinant
ACE2 (20 nM) was assessed using fluorgenic substrate
7-methoxycoumarin-Tyr-Val-Ala-Asp-Ala-Pro-Lys (2,4-dinitrophenyl).
Fluorescence under control conditions (100%, addition of buffer) and
after addition of a specific ACE2 inhibitor, MLN-4760, or ACE inhibitor
captopril at concentrations ranging from 100 pM to 100 mM). Each
data point represent mean7s.e. calculated from duplicate wells and
is expressed as percent of to the values obtained in control
experiments (buffer control measured in quintuplicate wells). The
lack of inhibition of MLN-4760 on tissue ACE activity is shown in
(b) (glomerular isolates) and (c) (renal cortex). Protein lysates from
isolated glomeruli or kidney cortex were incubated without (buffer
control) or with addition of MLN-4760 (1 mM). Glomeruli were pooled
from four mice. The values represent means of triplicate wells and
were set to 100% (buffer control).
Table 2 | Light microscopy findings
Control+vehicle STZ+vehicle STZ+MLN-4760
Mesangial matrix expansion 1.0070.00 2.5070.22* 3.8670.10#,$
Glomerular tuft area (mm2) 2350.4797.8 3071.2787.2* 3204.1767.9#
Glomerular cellularity (cells/gcs) 29.472.2 39.670.82* 34.1370.73#,$
Vascular thickness 1.0070.00 1.5570.24* 3.1970.26#,$
Inmunohistochemistry (tubulointerstitial area)
Fibronectin 1.4570.06 2.0670.25* 2.4070.12#
Collagen I 0.3770.06 1.5470.27* 2.1670.16#
H&E, hematoxylin and eosin stain; PAS, periodic acid-Schiff.
Data are expressed as means7s.e. *Po0.05 control+vehicle vs STZ+vehicle. #Pp0.05 control+vehicle vs STZ+MLN-4760. $Pp0.05 STZ+vehicle vs STZ+MLN-4760.
Mann–Whitney test.
Optical histology: mesangial matrix expansion, glomerular hypercellularity, glomerular hypertrophy, and vascular thickness were evaluated on H&E stain and PAS sections by
a nephropathologist.
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collagen I mRNA was increased in kidney cortex from the
vehicle-treated STZ mice as compared to mice from non-
diabetic control group (16.4274.72 vs 1.0470.14 respec-
tively, P¼ 0.010). MLN-4760 treatment had no significant
effect on collagen I mRNA expression as compared to STZ-
vehicle treated mice (13.0172.15 vs 16.4274.72 respectively,
P¼ 0.52).
Electron microscopy
Ultrastructural analysis of glomeruli from STZ-treated mice
showed increased mesangial matrix as compared to non-
diabetic control mice, and MLN-4760 administration to STZ-
treated mice was associated with a further increase in
mesangial matrix as compared to STZ mice treated with
vehicle (data not shown). Ultrastructural evaluation, in both
MLN-4760 and vehicle-treated STZ-mice, revealed focal
effacement of the foot processes, especially in the inter-
capillary region with aggregation of the intracellular actin
filaments (Figure 5).
In a quantitative analysis, we did not find significant
differences in podocyte number between STZ mice treated
with vehicle and MLN-4760 as compared to controls (open-
slit pore density: control 932749/mm, STZþ vehicle
1066745/mm, and STZþMLN-4760 1062756/mm. The
number of slit diaphragms discerned by tight pore density
was also not significantly different between the three groups:
control 241715/mm, STZ 272717/mm, and STZþMLN-
4760 279720/mm.
Renal ACE expression
Glomerular ACE staining was increased in STZ-treated mice
as compared to non-diabetic counterparts (Figure 6b and a,
respectively). In STZ mice receiving MLN-4760, the number
of glomeruli with strong ACE staining was increased as
compared to STZ mice treated with vehicle (65.4%76.2 vs
40.4%74.9, respectively, Po0.05; Figure 6, upper panel). In
renal vessels, ACE expression was also increased in the intima
of STZ group as compared to non-diabetic control group
(Figure 6, lower panel). In MLN-4760-treated STZ mice, the
number of vessels with strong ACE protein staining was
further increased as compared to STZ mice treated with
vehicle (61.3%76.2 vs 36.6%76.9, respectively, Po0.05;
Figure 6).
Non-diabetic control STZ+vehicle STZ+MLN-4760
a b c
Figure 3 | (a) Kidney sections from non-diabetic, (b) STZ-treated mice given vehicle, and (c) STZ-treated mice receiving MLN-4760. Periodic
acid-Schiff staining in glomerulus (original magnification  600): (b) STZ-treated mice given vehicle show mild mesangial expansion and
hypercellularity as compared with (a) non-diabetic mice. (c) STZ-treated mice given MLN-4760 show increased mesangial expansion as
compared to STZ-treated mice given (b) vehicle.
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Figure 4 | Light photomicrographs of kidney sections from (a and d)
non-diabetic controls, (b and e) STZ-mice vehicle treated, and
(c and f) STZ-mice given MLN-4760. (a–c) Low magnification
micrographs depicting relative atrophy of medulla and widening of
the cortex in STZ vehicle and (c) STZ MLN-4760-treated mice. Atrophy
of the medulla and its tubules is most notable in STZ MLN-4760
treated mice. (d–f) High magnification micrographs showing
hypertrophy of the cortex and its tubules in both STZ groups.
Enlargement of tubules seems to be similar in both groups, but
tubules with enlarged nuclei (red arrowheads) were readily seen
in the STZ MLN-4760 group, suggesting accentuated hypertrophic
response in this group.
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Since both glomerular and renal vascular ACE staining
showed directionally similar changes, we examined the
correlation of staining intensities between these two struc-
tures. A strong positive correlation in ACE staining intensity
was found between glomeruli and vessels from the same
sections (r¼ 0.91, Po0.001).
By immunohistochemistry, tubular ACE staining appeared
less intense in STZ-treated mice and was further decreased by
MLN-4760 administration (Figure 7a–c). The differences,
however, could not be reliably quantified owing to the strong
intensity of ACE staining at the tubular level.
Renal cortical ACE was therefore quantified by mRNA and
enzymatic activity levels. ACE mRNA was decreased in renal
cortex from the STZ mice treated with vehicle as compared to
non-diabetic controls (0.5170.07 vs 1.0170.08, respectively,
Po0.001), and MLN-4760 decreased ACE mRNA levels even
further (0.2770.03, Po0.05; Figure 7d). ACE enzymatic
activity was decreased in renal cortex from the STZ mice
Non-diabetic control STZ+vehicle STZ+MLN-4760
a b c
Figure 5 | Electron microscopy of glomeruli from (a) non-diabetic control mice, (b) STZ-treated mice given vehicle, (c) and STZ-treated mice
given MLN-4760: (arrows, b) STZ-treated mice given vehicle and (arrows, c) STZ-treated mice given MLN-4760 show focal effacement of the foot
processes especially in the intercapillary region with aggregation of the intracellular actin filaments as compared to non-diabetic controls
(original magnification  9500).
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Figure 6 | Immunohistochemistry of ACE in kidney sections from (a and e) non-diabetic controls, (b and f) STZ-treated mice given vehicle, and
(c, g) STZ-treated mice given MLN-4760 showing an example of glomerular and vascular ACE staining. In STZ-treated mice, ACE staining
within (b) glomerular tuft and (f) vascular vessels was more intense than in (a and e, respectively) non-diabetic controls. In STZ-treated mice
receiving MLN-4760, ACE staining within the (c) glomerular tuft and (g) vascular vessels was more intense than in (b and f, respectively)
STZ-treated mice given vehicle. Semiquantitative analysis of (d and h) ACE immunohistochemistry (see Materials and Methods). Strong ACE
staining was markedly increased within glomerular tuft and renal vessels from STZ-treated mice given vehicle in comparison with
(d and h, respectively) non-diabetic control mice. After MLN-4760 administration, strong ACE staining was further increased in comparison with
(d and h) STZ-treated mice given vehicle. Data are mean7s.e. *Po0.05 STZþ vehicle vs non-diabetic control mice. wPo0.05 STZþMLN-4760 vs
non-diabetic control mice. zPo0.05 STZþMLN-4760 vs STZþ vehicle.
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treated with vehicle as compared to non-diabetic controls,
and MLN-4760 decreased ACE enzymatic activity even
further (Figure 7e).
DISCUSSION
This study shows that chronic inhibition of ACE2 using a
specific pharmacological inhibitor, MLN-4760, worsens
kidney histological lesions in the STZ mouse model of
diabetes. Furthermore, MLN-4760 administration was asso-
ciated with enhanced expression of ACE in both glomeruli
and vasculature, suggesting that augmentation of this enzyme
may play a role in the observed glomerular lesions following
ACE2 inhibition. A dual mechanism of RAS activation at the
glomerular level and in renal vasculature may occur during
chronic ACE2 inhibition: decreased degradation of Ang II
which would result in Ang II accumulation, and increased
ACE expression which would result in enhanced formation of
Ang II. In addition, decreased degradation of Ang II is apt to
result in reduced formation of Ang 1-7, a hormone that is
increasingly recognized as antiproliferative.17–19
A recent study in an ACE2 knockout showed the
development of glomerular lesions.8 The renal lesions
occurred in male, but not female mice, and this was a late
event, as it was not seen until animals were almost 1-year
old.8 In our study, by contrast, the administration of an ACE2
inhibitor for only 4 weeks to younger mice pre-treated with
STZ resulted in worsening of albuminuria and glomerular
histological lesions, namely mesangial matrix expansion. Of
note, these findings were seen in female mice. Thus, in the
setting of hyperglycemia, ACE2 inhibition appears to worsen
glomerular injury. Tubular changes associated with MLN-
4760 administration included tubular hypertrophy in cortical
tubules. Consistent with cortical hypertrophy, the kidney/
body weight ratio was also increased. The known hyper-
trophic effects of Ang II on proximal tubular cells20,21 could
explain these findings. After ACE2 inhibition, Ang II should
increase, whereas Ang 1-7 should decrease. There is emerging
evidence showing that Ang 1-7 may attenuate the hyper-
trophy caused by Ang II.22,23 In contrast to these findings in
the cortical areas, renal medulla and papilla were clearly
atrophic in mice treated with MLN-4760 (Figure 4). It should
be noted that in an ACE knockout, marked medullary and
papillary atrophy are prominent findings.24 In our study, the
observed decrease in ACE tubular activity may also be the
mechanism involved in the atrophic tubular lesions seen in
the medulla and papilla.
MLN-4760 resulted in a significant increase in albumin
excretion, but the responses were variable as it is often the
case in diabetes-induced renal injury (Figure 1). We did not
measure blood pressure in this study, but we have data in
diabetic db/db mice and db/m controls, given this compound
for a longer period of time of 16 weeks without significant
effect on blood pressure (Ye et al., unpublished 2006). In our
study, there was no significant difference in plasma Ang II
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Figure 7 | Upper panel: Immunohistochemistry of ACE in kidney sections from (a) non-diabetic mice, (b) STZ-treated mice given vehicle,
and (c) STZ-treated mice given MLN-4760 showing an example of proximal tubular ACE staining. In (b) STZ-treated mice, ACE staining within
proximal tubules was less intense than in (a) non-diabetic controls. In (c) STZ-treated mice receiving MLN-4760, ACE staining within the
proximal tubules was less intense than in (b) STZ-treated mice given vehicle. These findings, however, could not be quantified because of the
strong staining at the tubular level in the three groups. Lower panel: (d) ACE mRNA and (e) ACE enzymatic activity in kidney cortex
preparations (largely representing renal cortical tubules) from non-diabetic control, STZ-treated mice given vehicle, and STZ-treated mice
receiving MLN-4760. The pattern of ACE expression in renal tubules is the reverse than that observed in glomeruli and renal vessels (Figure 6).
Control: non-diabetic control mice; STZþ vehicle: STZ-treated mice given vehicle; STZþMLN-4760: STZ-treated mice given MLN-4760. Data
are mean7s.e. *Po0.05 STZþ vehicle vs non-diabetic control mice. wPo0.05 STZþMLN-4760 vs non-diabetic control mice. zPo0.05
STZþMLN-4760 vs STZþ vehicle.
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levels in STZ animals treated with MLN-4760 and those
treated with vehicle. This is an agreement with studies in
ACE2 knockout where the levels of plasma Ang II were not
significantly different under baseline conditions.10 In this
study, Ang II levels increased only after Ang II infusion.10 We
did not measure kidney Ang peptides in this study, as we
think that the results would not be easy to interpret unless if
performed separately in renal tubules and glomeruli. The
isolation of tubules and glomeruli for separated measure-
ments would be needed to examine properly the levels of Ang
peptides.
Our studies using a pharmacological probe to inhibit
ACE2 enzyme have advantages and disadvantages as
compared to ACE2 knockout in terms of dissecting the role
of this enzyme in kidney disease. Since the inhibitor used,
MLN-4760, was given to adult animals, the potential effects
of ACE2 ablation on kidney development, in which the RAS
plays an important role, were avoided.25 Other potential
advantage is that pharmacological ACE2 inhibition does not
produce complete enzymatic inhibition, a situation that
resembles human disease more closely, and thereby allows for
the assessment of the relative importance of ACE2. In the
present study, the in vivo administration of MLN-4760 for 4
weeks resulted in marked inhibition of ACE2 activity in renal
cortex. The specificity of this compound for ACE2 was
further demonstrated using mouse recombinant ACE2
(Figure 2a), and by showing that MLN-4760 has no effect
on ACE activity in isolated glomeruli or renal cortex
(Figure 2b and c).
A major finding of our study is that glomerular and
vascular expression of ACE was increased after chronic ACE2
inhibition using MLN-4760 administration (Figure 4). In this
respect, it is important to note that a modest genetic increase
in ACE levels in mice with three copies of the ACE gene
resulted in an increase in albuminuria, probably as a result of
RAS overactivity, when mice were made diabetic by STZ.26
This suggests that a high constitutive level of ACE is
important for the development of glomerular damage, at
least in the setting of diabetes. ACE and ACE2 work in
concert to regulate the level of angiotensin peptides.27 A
combination of high ACE and low ACE2 is apt to increase
Ang II formation, while decreasing Ang II degradation.7
Moreover, ACE2 inhibition would decrease Ang 1-7 forma-
tion, a peptide that has vasodilatory and antiproliferative
actions.17–19,22 We assume that the increased expression of
ACE in the glomerulus reflects an augmentation of ACE in
glomerular endothelial cells7 and in the endothelium of the
renal vasculature. We cannot rule out, however, the
possibility that an increase of glomerular ACE also involves
mesangial cells where this enzyme is also present.28,29
It is possible that endothelial ACE overexpression, after
ACE2 inhibition, is the result of Ang II overactivity. Since
Ang II upregulates gene expression and activity of ACE,30 we
surmise that Ang II overactivity may be a plausible
explanation for our findings of increased glomerular and
vascular ACE expression. It should be noted, however, that
this effect of Ang II is tissue-specific31 and that other studies
showed no effect of Ang II on ACE secretion, whereas
another study showed that chronic Ang II infusion had a
weak inhibitory effect of ACE gene expression in the lung,
testis, or brain.31 Other factors that had been shown to
upregulate endothelial ACE include aldosterone and vascular
endothelial growth factor.32,33 The latter seems a reason-
able candidate, because it has been found upregulated in
models of diabetic kidney disease and also after Ang II
administration.34,35
Our study also confirms that there is a dichotomy between
glomerular ACE and tubular ACE expression.6,7,15 Specifi-
cally, in mice made diabetic by STZ, glomerular and vascular
ACE was increased, whereas in renal cortex, a preparation
that largely contains renal tubules, ACE was decreased both at
the level of mRNA and enzymatic activity when compared to
non-diabetic controls. Of note, similar results in terms of
reduced renal cortex ACE enzymatic activity were found in
STZ-treated rats by Anderson et al.,36,37 and more recently by
us in the db/db model of type 2 diabetes.7,15 Interestingly, we
now find that the administration of a specific ACE2 inhibitor
decreases tubular ACE activity while increasing glomerular
ACE expression, thereby replicating and exaggerating the
pattern of altered ACE expression seen in diabetic kidneys.
We think that the findings in the glomeruli and renal
vasculature are more relevant to the pathology of diabetic
kidney disease.
In conclusion, pharmacological ACE2 inhibition in STZ
mice increases albuminuria and results in worsening of renal
histological lesions, namely glomerular mesangial matrix
expansion. ACE2 inhibition is associated with increased ACE
expression in glomeruli and renal vessels. We postulate that
glomerular and vascular injury associated with ACE2
inhibition is modulated, in part, by enhanced ACE expression
leading to increased Ang II formation. This is apt to amplify
the renal injury primarily caused by ACE2 inhibition, which
leads to impaired Ang II degradation, and decreased Ang 1-7
formation.
MATERIALS AND METHODS
Animal models
All studies were conducted with the review and approval of the
Institutional Animal Care and Use Committee. STZ-treated mice
were used as a model of type 1 diabetes. Diabetes was induced in
female C57BL/6J mice by two intraperitoneal injections of STZ
(Sigma-Aldrich, St Louis, MO, USA), at a dose of 150 mg/g body
weight in 50 ml of sterile 0.05 M sodium citrate (pH 4.5). The non-
diabetic control group received an equal volume of vehicle, sodium
citrate. Mice did not receive insulin and at 2 weeks after diabetes
induction, STZ-treated mice were divided into two groups. The first
group received a specific ACE2 inhibitor, MLN-4760 (kind gift from
Millennium Pharmaceuticals, Cambridge, MA, USA) that was
injected subcutaneously (40 mg/kg/BW, every other day) (STZþ
MLN-4760). The untreated STZ group received equal volumes
of sterile phosphate-buffered saline as a vehicle (STZþ vehicle).
Mice were killed after 4 weeks of ACE2 inhibitor treatment at
19 weeks of age, and the last MLN-4760 dose was given about 24 h
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before killing. Animal characteristics at killing are summarized in
Table 1.
Blood was obtained from the tail vein and glycemia was assessed
using One Touch Ultra Glucometer (LifeScan, Mountain View, CA,
USA). Spot urine samples were collected before killing the mice.
Urine albumin and urine creatinine were determined using Albuwell
M and Creatinine Companion kit, respectively, from Exocell
(Philadelphia, PA, USA) according to the manufacturer’s instruc-
tions. Results are expressed as albumin/creatinine ratio (mg/mg).
Tissue preparation and morphological studies
Pentobarbital sodium was administered intraperitoneally, and
kidneys were perfused with ice-cold PBS to flush out blood. Kidneys
were quickly removed and weighed for morphological analysis in all
experimental groups. Renal mass index was determined as the ratio
of the weight of both kidneys per body weight. For pathohistological
evaluation, kidneys were cut longitudinally and fixed with 10%
buffered formalin phosphate (Fisher Scientific, Pittsburg, PA, USA)
for overnight. Sections were stained with hematoxylin and eosin and
periodic acid-Schiff.
Glomerular hypertrophy was quantified by measuring the
glomerular tuft cross-sectional area with a computer image analysis
system (Image J, NIH). Glomerular hypertrophy was assessed by
measuring the tuft area from glomeruli in which the vascular pole
was evident (using at least 20 glomeruli per section). This was
performed to reduce the possibility of including tangentially cut
glomeruli.38 Glomerular images were digitalized using a colour
video camera attached to a Nikon microscope ( 60 objective
magnification) After digitalization, the glomerular tuft was traced,
and the areas were calculated using Image J (NIH) analysis software.
Mesangial matrix expansion was evaluated by an experienced,
masked renal pathologist using semiquantitative score (grades 1–4):
1 for normal or minimal, 2 for mild, 3 for moderate, and 4 for
diffuse mesangial matrix expansion.39,40 In addition, tubular lesions
were assessed by the following semiquantitative score (grades 1–4):
grade 1¼ 1–25% lesions, grade 2¼ 26–50% lesions, grade 3¼
51–75%, and grade 4475% lesions.16
Immunohistochemistry
Slides were incubated for 1 h with a rat monoclonal ACE antibody
(5C4) (kind gift of Dr Sergei Danilov) diluted at 1:2000, rabbit
fibronectin antibody (Sigma-Aldrich) diluted at 1:400, or purified
rabbit collagen type I antibody (Cedarlane, Canada) diluted at
1:500. Sections for ACE staining were washed with Tris-buffered
saline Tween (DAKO, Carpinteria, CA, USA), incubated with
biotinylated rabbit anti-rat IgG (Vector Labs, Burlington, Ontario,
Canada) followed by peroxidase-labeled streptavidin (DAKO).
Sections for fibronectin and collagen I staining were washed and
incubated with goat anti-rabbit IgG conjugated with peroxidase-
labeled polymer (DAKO). Peroxidase labeling was revealed using a
liquid diaminobenzidine substrate-chromogen system (DAKO).
Sections were counterstained with hematoxylin (Sigma-Aldrich)
and dehydrated, mounted with Permount (Fisher) and coverslipped.
Sections were examined and photographed with a Zeiss microscope.
Non-immune antibody was used as control for specificity.
To assess levels of ACE expression in glomerular tuft and renal
vasculature, a semiquantitative analysis of the immunoperoxidase-
stained sections was performed based on a pathologist established
score as follows: 1¼ no staining; 2¼weak staining; 3¼ strong
staining, as described previously in other studies.7,41,42 Sections were
examined by three different masked observers, who assessed staining
intensity of 100 glomeruli and 20 vessels from each slide. The data
were expressed as percentage of glomeruli and renal vessels in strong
staining category.
Fibronectin and collagen I expression in the tubulointerstitium
was assessed by a semiquantitative analysis. The expression score
from 0 to 3 was based on the intensity and distribution of
fibronectin and collagen I, in which 0 represents no expression, 1
mild expression, 2 moderate expression, and 3 severe expression. In
each section, the score was counted in 10 random fields under
 200 magnification, and the score was averaged for each field.43,44
Electron microscopy
Kidney cortex was cut into 1-mm3 blocks and fixed in 2.5%
glutaraldehyde in 0.1 M sodium cacodylate buffer at 41C for
overnight. Tissue blocks were post-fixed with 2% osmium tetroxide
in 0.1 M sodium cacodylate buffer for 1 h and dehydrated in graded
ethanol. Blocks were infiltrated in epon/araldite resin, transferred
into BEEM capsules with resin and polymerized at 601C for 24 h.
The 90 nm sections were stained with uranyl acetate and lead citrate,
and examined using a JEOL 1220 electron microscope. Photo-
micrographs of the GBM were also analyzed for the density of open
and ‘tight’ slit pores between the podocyte foot processes, according
to published methods.45 The number of each type of slit pore were
counted and divided by the GBM length (mm) to arrive at the linear
density.
ACE2 and ACE activity assay
Kidney cortex and glomerular samples were homogenized in a
buffer consisting of (in mM) 50 4-(2-hydroxyethyl)-1-piperazi-
neethanesulfonic acid, pH 7.4, 150 NaCl, 0.5% Triton X-100, 0.025
ZnCl2, and 1.0 phenylmethylsulfonyl fluoride and then clarified by
centrifugation at 10 000 g for 15 min. To each well, 88 ml of a diluted
tissue sample (10mg of total protein/well for kidney tissue extracts
for ACE2 and 1 mg/well for ACE measurement) was added, along
with 10 ml of buffer (with the respective inhibitor), and the reaction
was initiated by the addition of 2 ml of the substrate (1.0 mM, final
concentration). The plates were read using a fluorescence plate
reader FLX800 (BIOTEK Instruments Inc., Winooski, VT, USA) at
an excitation wavelength of 320 nm and an emission wavelength of
400 nm.15
Glomerular and kidney cortex ACE enzymatic activity was also
assessed with a colorimetric method, as described previously6 (ACE
color; Fujirebio Diagnostics Inc., Malvern, PA, USA).6,46 To establish
whether MLN-4760 has an effect on ACE activity, protein lysates
from kidney cortex and isolated glomeruli (obtained by a magnetic
beads methods as described previously in Takemoto et al.47) were
incubated with or without the addition of MLN-4760 (106 M) or
captopril (106 M).
RNA isolation and reverse transcriptase/real-time
polymerase chain reaction
Quantitative real-time polymerase chain reaction of kidney tissue
samples was performed using the TaqMan Gold RT-PCR kit and ABI
Prism 7700 (Applied Biosystems, Foster City, CA, USA) sequence-
detection system. Primers and probes for ACE were designed using
Primer Express software (Applied Biosystems). The forward primer,
reverse primer, and probe were as follows: ACE gene: 5-CAGAAT
CTACTCCACTGGCAAGGT-3, 5-TCGTGAGGAAGCCAGGATGT-3,
and 5-FAM-CAACAAGACTGCCACCTGCTGGTCC-TAMRA-3. ACE2
gene: 5-GGATACCTACCCTTCTACATCAGC-3, 5-CTACCCCACA
TATCACCAAGCA-3, and 5-FAM-CCA CTGGATGCCTCCCTGC
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CC-TAMRA-3. Fibronectin gene: 5-AGATGTGCAAGCTGACAGAG
ACGA-3, 5-TGTCTGGGTGACTTTCCTTGCTCA-3, and 5-FAM-
ACAGTTGGTCACCCTGTTCTGCTTCA-TAMRA-3. Collagen I gene:
5-TGCTTTCTGCCCGGAAGA-3, 5-GGGATGCCATCTCGTCCA-3,
and 5-FAM-CCAGGGTCTCCCTTGGGTCCTACATCT-TAMRA-
3. As internal control served glyceraldehyde-3-phosphate dehydro-
genase (G3PDH): with forward primer, 5-CAGAAGACTGTGGAT
GGCCCCTC-3; reverse primer, 5-TGCACCACCAACTGCTTAG-3;
and probe, 5-FAM-CAGAAGACTGTGGATGGCCCCTC-TAMRA-3.
Reverse transcription was carried out for 30 min at 481C. The
samples were heated to 951C for 10 min, and 40 cycles of a two-step
polymerase chain reaction were performed (951C for 15 s and 601C
for 60 s). The ACE, fibronectin and collagen I mRNA levels of the
samples were normalized to their G3PDH contents. Experiments
were carried out in triplicate for each data point.
ANG II levels in plasma
Blood samples were collected in tubes kept on ice containing
ethylenediamine tetraacetic acid (25 mM), o-phenanthroline
(0.44 mM), pepstatin A (0.12 mM), and p-hydroxymercuribenzoic
acid (1 mM), and then centrifuged (3000 g). The plasma was
removed and stored at 801C until further processing. Angiotensin
peptides were extracted from the plasma using reverse phase phenyl
silica columns (100 mg; Amersham Biosciences, Buckinghamshire,
UK) as per manufacturer’s instructions. The quantity of Ang II in
the extract was measured by enzyme-linked immunosorbent assay
using commercially available kit (SPIBio, Montigny-le-Bretonneux,
France).48
Statistical analyses
The data were reported as mean7s.e. Significance was defined as
Po0.05. For comparisons between two independent means, the
non-parametric Mann–Whitney U-test was used. When more than
two independent means were compared, Kruskall–Wallis test was
performed. A Pearson’s test was used for correlation between two
variables. SPSS version 12.0 for Windows was used for statistical
analyses.
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